Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline Review, H2 2020

July 2020 | 149 pages | ID: P8FEC46AC5EEN
Global Markets Direct

Abstracts

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cholangitis - Pipeline Review, H2 2020, provides an overview of the Primary Biliary Cholangitis (Gastrointestinal) pipeline landscape.
Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cholangitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Biliary Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 8, 3, 1, 1 and 5 respectively.
Primary Biliary Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cholangitis (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Primary Biliary Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Primary Biliary Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Primary Biliary Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cholangitis (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cholangitis (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Primary Biliary Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Overview
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Development
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Assessment
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Companies Involved in Therapeutics Development
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Drug Profiles
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Abcuro Inc, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Allergan Ltd, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Cadila Healthcare Ltd, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Calliditas Therapeutics AB, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Dr. Falk Pharma GmbH, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Eli Lilly and Co, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Genfit SA, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by GenKyoTex SA, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Gilead Sciences Inc, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by GlaxoSmithKline Plc, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Kowa Co Ltd, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by MYR GmbH, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by NGM Biopharmaceuticals Inc, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Novartis AG, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by PRISM Pharma Co Ltd, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Virobay Inc, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects, H2 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Abcuro Inc
Alexion Pharmaceuticals Inc
Allergan Ltd
Cadila Healthcare Ltd
Calliditas Therapeutics AB
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Dr. Falk Pharma GmbH
Eli Lilly and Co
Genfit SA
GenKyoTex SA
Gilead Sciences Inc
GlaxoSmithKline Plc
Hanmi Pharmaceuticals Co Ltd
Kowa Co Ltd
MYR GmbH
NGM Biopharmaceuticals Inc
Novartis AG
PRISM Pharma Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Virobay Inc